Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables - Net: 2013-2025

Historic Receivables - Net for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $146.8 million.

  • Amphastar Pharmaceuticals' Receivables - Net rose 5.14% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year increase of 5.14%. This contributed to the annual value of $136.3 million for FY2024, which is 18.57% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Receivables - Net is $146.8 million, which was up 10.40% from $133.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Receivables - Net high stood at $146.8 million for Q3 2025, and its period low was $67.9 million during Q2 2021.
  • Moreover, its 3-year median value for Receivables - Net was $133.0 million (2025), whereas its average is $128.1 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Receivables - Net decreased by 6.12% in 2022, and later spiked by 54.33% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Receivables - Net (Quarterly) stood at $78.8 million in 2021, then rose by 12.69% to $88.8 million in 2022, then increased by 29.43% to $114.9 million in 2023, then rose by 18.57% to $136.3 million in 2024, then grew by 5.14% to $146.8 million in 2025.
  • Its Receivables - Net stands at $146.8 million for Q3 2025, versus $133.0 million for Q2 2025 and $144.6 million for Q1 2025.